249764-10-1

Upstream product

• 151-50-8 potassium cyanide 
• 249764-06-5 {2-[5-(tert-butyl-dimethyl-silanyloxy)-2,4-dimethoxy-3-methyl-phenyl]-1-formyl-ethyl}-carbamic acid 9H-fluoren-9-ylmethyl ester 

Downstream Products

• 249764-12-3 C₃₈H₄₉N₃O₆Si 
• 429687-52-5 {1-[5-(tert-butyl-dimethyl-silanyloxy)-2,4-dimethoxy-3-methyl-benzyl]-2-cyano-2-[2-(4-hydroxy-butyl)-morpholin-4-yl]-ethyl}-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 477566-53-3 {2-{2-[4-(tert-butyl-dimethyl-silanyloxy)-butyl]-morpholin-4-yl}-1-[5-(tert-butyl-dimethyl-silanyloxy)-2,4-dimethoxy-3-methyl-benzyl]-2-cyano-ethyl}-carbamic acid 9H-fluoren-9-ylmethyl ester 

Relevant academic research and scientific papers

A solid-supported, enantioselective synthesis suitable for the rapid preparation of large numbers of diverse structural analogues of (-)-saframycin A

A 10-step solid-supported, enantioselective synthesis suitable for the rapid preparation of large numbers of diverse structural analogues of saframycin A is described. The synthetic route, which bears analogy to solid-phase peptide synthesis, involves the

NOVEL SAFRAMYCIN ANALOGS AS THERAPEUTIC AGENTS

The present invention is directed to saframcyin analogs that are useful in the treatment of cancer. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

NOVEL SAFRAMYCIN ANALOGS AS THERAPEUTIC AGENTS

The present invention is directed to saframcyin analogs that are useful in the treatment of cancer. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.